BRPI0804102A2 - pharmaceutical composition comprising plant extract and hemostatic agent and process for the preparation thereof - Google Patents
pharmaceutical composition comprising plant extract and hemostatic agent and process for the preparation thereof Download PDFInfo
- Publication number
- BRPI0804102A2 BRPI0804102A2 BRPI0804102-4A BRPI0804102A BRPI0804102A2 BR PI0804102 A2 BRPI0804102 A2 BR PI0804102A2 BR PI0804102 A BRPI0804102 A BR PI0804102A BR PI0804102 A2 BRPI0804102 A2 BR PI0804102A2
- Authority
- BR
- Brazil
- Prior art keywords
- present
- composition according
- plant extract
- hemostatic agent
- agents
- Prior art date
Links
- 229940030225 antihemorrhagics Drugs 0.000 title claims abstract description 26
- 239000002874 hemostatic agent Substances 0.000 title claims abstract description 26
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 24
- 239000000419 plant extract Substances 0.000 title claims abstract description 21
- 238000000034 method Methods 0.000 title claims 11
- 238000002360 preparation method Methods 0.000 title description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000004615 ingredient Substances 0.000 claims abstract description 14
- 239000002674 ointment Substances 0.000 claims abstract description 11
- 239000011787 zinc oxide Substances 0.000 claims abstract description 11
- 239000003937 drug carrier Substances 0.000 claims abstract description 9
- 229940002386 calendula officinalis extract Drugs 0.000 claims abstract description 6
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 claims abstract description 5
- 241000283690 Bos taurus Species 0.000 claims abstract description 4
- 241000282324 Felis Species 0.000 claims abstract description 4
- 241001465754 Metazoa Species 0.000 claims abstract description 4
- 241000282465 Canis Species 0.000 claims abstract description 3
- 241000283086 Equidae Species 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 30
- 240000001432 Calendula officinalis Species 0.000 claims description 24
- 235000005881 Calendula officinalis Nutrition 0.000 claims description 14
- 241000196324 Embryophyta Species 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 9
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 claims description 7
- 235000003880 Calendula Nutrition 0.000 claims description 7
- 229910044991 metal oxide Inorganic materials 0.000 claims description 7
- 150000004706 metal oxides Chemical class 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000003086 colorant Substances 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 235000013355 food flavoring agent Nutrition 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 239000002562 thickening agent Substances 0.000 claims description 3
- 239000013008 thixotropic agent Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 230000035876 healing Effects 0.000 abstract description 9
- 230000000699 topical effect Effects 0.000 abstract description 8
- 229940037003 alum Drugs 0.000 abstract description 4
- 235000014692 zinc oxide Nutrition 0.000 description 7
- 230000002421 anti-septic effect Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000002439 hemostatic effect Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- YQEMORVAKMFKLG-UHFFFAOYSA-N 2-stearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 244000141009 Hypericum perforatum Species 0.000 description 2
- 235000017309 Hypericum perforatum Nutrition 0.000 description 2
- 244000042664 Matricaria chamomilla Species 0.000 description 2
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 229940082500 cetostearyl alcohol Drugs 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 229910052814 silicon oxide Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 2
- 229940098465 tincture Drugs 0.000 description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- 235000007754 Achillea millefolium Nutrition 0.000 description 1
- 240000000073 Achillea millefolium Species 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241001233914 Chelidonium majus Species 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 244000166124 Eucalyptus globulus Species 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 235000015266 Plantago major Nutrition 0.000 description 1
- 244000010922 Plantago major Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- 235000002912 Salvia officinalis Nutrition 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003501 anti-edematous effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000007765 cera alba Substances 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 239000013003 healing agent Substances 0.000 description 1
- 239000000976 ink Substances 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000002879 macerating effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000011474 orchiectomy Methods 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000003331 prothrombotic effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- RNWHGQJWIACOKP-UHFFFAOYSA-N zinc;oxygen(2-) Chemical class [O-2].[Zn+2] RNWHGQJWIACOKP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A presente invenção situa-se no campo das composições farmacêuticas que compreendem extrato vegetal, um agente hemostático e pelo menos um ingrediente com ação cicatrizante. Especificamente, a composição farmacêutica da presente invenção é de uso tópico e compreende extrato de Calendula officinalis, sulfato de aluminio e potássio (Alúmen), óxido de zinco em veículo farmaceuticamente aceitável. A composição farmacêutica da presente invenção se apresenta preferencialmente na forma de uma pomada que pode ser utilizada tanto em humanos como em animais tais como caninos, felinos, bovinos e/ou eqüinos.The present invention is in the field of pharmaceutical compositions comprising plant extract, a hemostatic agent and at least one healing action ingredient. Specifically, the pharmaceutical composition of the present invention is of topical use and comprises Calendula officinalis extract, potassium aluminum sulfate (Alum), pharmaceutically acceptable carrier zinc oxide. The pharmaceutical composition of the present invention is preferably in the form of an ointment that can be used in both humans and animals such as canines, felines, cattle and / or horses.
Description
Relatório Descritivo de Patente de InvençãoPatent Invention Descriptive Report
Composição Farmacêutica Compreendendo Extrato Vegetal eAgente Hemostático e Processo Para o Preparo da MesmaPharmaceutical Composition Understanding Plant Extract and Hemostatic Agent and Process for Preparing It
Campo da InvençãoField of the Invention
A presente invenção situa-se no campo das composições farmacêuticasque compreendem extrato vegetal, um agente hemostático e pelo menos umingrediente opcional—com possuindo—ação cicatrizante;—anti séptica—ehemostática. Especificamente, a composição farmacêutica da presenteinvenção é de uso tópico e compreende extrato de Calêndula officinalis,, sulfatode alumínio e potássio (Alúmen), oxido de zinco em veículo farmaceuticamenteaceitável. A composição farmacêutica da presente invenção se apresentapreferencialmente na forma de uma pomada que pode ser utilizada tanto emhumanos como em animais tais como caninos, felinos, bovinos e/ou eqüinos.The present invention is in the field of pharmaceutical compositions which comprise plant extract, a hemostatic agent and at least one optional ingredient - with having - healing action; - antiseptic - ehemostatic. Specifically, the pharmaceutical composition of the present invention is of topical use and comprises extract of calendula officinalis, potassium aluminum sulfate (alum), zinc oxide in a pharmaceutically acceptable carrier. The pharmaceutical composition of the present invention is preferably in the form of an ointment that can be used in both humans and animals such as canines, felines, cattle and / or horses.
Antecedentes da InvençãoBackground of the Invention
Extratos vegetais têm sido amplamente utilizados na composição deformulações farmacêuticas. Os princípios ativos de origem vegetal podem serobtidos das folhas, flores, cascas e raízes das plantas. O processo geral deobtenção de um extrato vegetal envolve trituração da planta no solventeescolhido, agitação, maceração (período de descanso em que se mergulhauma substância sólida em um líquido, para extrair-lhe as características) e porfim a filtração do líquido.Plant extracts have been widely used in the composition of pharmaceutical formulations. The active ingredients of plant origin can be obtained from the leaves, flowers, bark and roots of plants. The general process of obtaining a plant extract involves crushing the plant in the chosen solvent, stirring, macerating (resting period when a solid substance is immersed in a liquid to extract its characteristics) and finally filtering the liquid.
A calêndula (Calêndula officinalis L) é uma planta de origem européia,pertencente à família Asteraceae. As plantas de Calêndula officinalisencontradas no Brasil produzem flores de tamanho variado (3 a 9 cm) e coresheterogêneas. A Calêndula officinalis encontra-se difundida no mundo e estábem aclimatada no Brasil, sendo comercializada em farmácias onde éempregada em diversos preparados fitoterápicos e cosméticos. O extrato dasflores de calêndula é indicado no tratamento de inflamações da pele, demucosas, na cicatrização de feridas e queimaduras leves. Vários trabalhos comcalendula têm correlacionado sua atividade biológica com sua estruturaquímica: saponinas triterpenoídicas tem atividade anti-tumoral, triterpenóidestem atividade antiinflamatória tópica, flavonóides, apresentam atividadeantiinflamatória e éster triterpenodiol, atividade anti-edema.Marigold (Marigold officinalis L) is a plant of European origin, belonging to the family Asteraceae. Marigold officinalis plants found in Brazil produce flowers of varying size (3 to 9 cm) and heterogeneous colors. Calendula officinalis is widespread in the world and is well acclimated in Brazil and is sold in pharmacies where it is used in various herbal and cosmetic preparations. Marigold flower extract is indicated for the treatment of skin inflammation, demining, wound healing and minor burns. Several studies with calendula have correlated its biological activity with its chemical structure: triterpenoid saponins have anti-tumor activity, triterpenoid have topical anti-inflammatory activity, flavonoids have anti-inflammatory activity and triterpenediol ester anti-edema activity.
Além disso, compostos inorgânicos como óxidos metálicos sãocomumente utilizados como agentes hemostáticos em composiçõesfarmacêuticas, sendo que vários estudos demonstram sua eficácia e revelamcomposições com finalidade de cicatrização.In addition, inorganic compounds such as metal oxides are commonly used as hemostatic agents in pharmaceutical compositions, and several studies have shown their efficacy and healing compounds.
Diante destes fatos, os inventores da presente invenção consideraramoportuna a possibilidade de desenvolver formulações compreendendo extratosde Calendula officinalis em conjunto com agentes hemostáticos, em umacomposição farmacêutica para uso tópico.In view of these facts, the inventors of the present invention considered it expedient to develop formulations comprising Calendula officinalis extracts together with hemostatic agents in a pharmaceutical composition for topical use.
Não foram encontrados no estado da técnica documentos relativos acomposições farmacêuticas para uso tópico com ação cicatrizante e/ouantiséptica contendo a combinação de extrato de Calendula officinalis e de pelomenos um agente hemostático, como proposto na presente invenção. Osdocumentos mais relevantes encontrados serão descritos a seguir.No prior art relating to pharmaceutical compositions for topical use with healing and / or antiseptic action containing the combination of Calendula officinalis extract and a hemostatic agent as proposed in the present invention has been found. The most relevant documents found will be described below.
O documento WO 1998/50055 relata uma pomada para tratamento dequeimaduras e outras doenças da pele contendo extrato de Calendulaofficinalis, óleo de girassol, óleo de oliva, incenso, colônia, cera branca deabelha, bismuto subgálico e cânfora. Neste documento, o extrato de Calendulaofficinalis é utilizado em proporções que variam de 1 a 2% e em nenhummomento é proposto ou sugerido o uso de agentes hemostáticos.WO 1998/50055 reports an ointment for the treatment of burns and other skin conditions containing Calendulaofficinalis extract, sunflower oil, olive oil, incense, cologne, white beeswax, subgallic bismuth and camphor. In this document, Calendulaofficinalis extract is used in proportions ranging from 1 to 2% and at no time is the use or suggestion of hemostatic agents suggested.
O documento WO 1997/42963 relata uma "pomada verde" utilizada notratamento de queimaduras e doenças da pele que compreende vários tipos deplantas tais como Chelidonium majus, Plantago major, Matricaria chamomilla,Achillea millefolium, Calendula officinalis, Hypericum perforatum, Eucalyptusglobus, Oleum olivarum e cera amarela de abelha Cera fiava. Nestedocumento, a concentração de C.officinalis utilizada varia de 1,5 a 2,5% e emnenhum momento é proposto ou sugerido o uso de agentes hemostáticos.O documento WO 2006/117516 relata uma composição para uso tópicocom função bactericida contra Staphylococcus aureus e Escheríchia coli queutiliza extrato de Calendula offícinalis. Entretanto, neste documento, o extratode C. offícinalis tem a função de ser um agente aromatizante, e não, um agentecicatrizante e anti-séptico como proposto na presente invenção. Ainda emnenhum momento é proposto ou sugerido o uso de agentes hemostáticos.WO 1997/42963 reports a "green ointment" used for burn and skin disease treatment comprising various types of plants such as Chelidonium majus, Plantago major, Matricaria chamomilla, Achillea millefolium, Calendula officinalis, Hypericum perforatum, Eucalyptusglobus, Oleum olivarum and yellow beeswax Wax spun. In this document, the concentration of C.officinalis used ranges from 1.5 to 2.5% and at no time is the proposed or suggested use of hemostatic agents. WO 2006/117516 reports a composition for topical use with bactericidal function against Staphylococcus aureus and Escheríchia coli that uses Calendula offícinalis extract. However, in this document, C. offícinalis extract has the function of being a flavoring agent, not an antiseptic healing agent as proposed in the present invention. At no time is the proposed or suggested use of hemostatic agents.
O documento WO 2005/063266 relata uma composição para uso tópicoque utiliza o extrato de Calendula offícinalis e Hypericum perforatum quecompreendem peptídeos de baixo pelo molecular e aminoácidos livres. Acomposição compreende ainda ácidos graxos insaturados, vitaminas, mineraise microelementos. Não há menção quanto ao uso de agente hemostático,como proposto na presente invenção. Especificamente, a composição descritaneste documento destina-se para o tratamento da psoríase.WO 2005/063266 discloses a composition for topical use using the extract of Calendula offícinalis and Hypericum perforatum which comprises low molecular hair peptides and free amino acids. Accompanying also comprises unsaturated fatty acids, vitamins, trace elements and microelements. There is no mention as to the use of hemostatic agent as proposed in the present invention. Specifically, the composition described in this document is intended for the treatment of psoriasis.
O documento EP 1 707 213 relata uma composição para usofarmacêutico que compreende o extrato/tintura de Calendula offícinalis,Matricaria recutita e Salvia offícinalis, veículos farmaceuticamente aceitáveiscomo pomadas, cremes, emulsões ou géis que é destinada ao tratamento deeritematoses cutâneas. No entanto em nenhum momento é proposto ousugerido o uso de agentes hemostáticos.EP 1 707 213 discloses a pharmaceutical composition comprising the extract / tincture of Calendula officinalis, Matricaria recutita and Salvia officinalis, pharmaceutically acceptable carriers such as ointments, creams, emulsions or gels which is intended for the treatment of skin deeritis. However, the use of hemostatic agents is not proposed at any time.
Os óxidos metálicos possuem diversos usos conhecidos. Podem serutilizados como filtros solares físicos, conforme descrito nos documentos US6,749,838, US 6,267,949, EP 786982, WO 07/048057, US 2008/031832, WO94/24998; usados como pigmentos em tintas como descrito nos documentosUS 6,700,112, EP 379746, US 5,916,947, US 5,656,074, WO 05/071032, US4,407,997; usados como fonte de zinco em alimentos, conforme descrito nosdocumentos US 6,156,355, WO 05/058052; usado também na manufatura decomponentes eletrônicos, devido a sua alta condutividade, conforme descritonos documentos US 6,813,137, EP 1770074, WO 06/138071. No entanto,poucos documentos descrevem seu uso em composições cicatrizantes.Metal oxides have several known uses. They may be used as physical sunscreens as described in US 6,749,838, US 6,267,949, EP 786982, WO 07/048057, US 2008/031832, WO94 / 24998; used as pigments in inks as described in US 6,700,112, EP 379746, US 5,916,947, US 5,656,074, WO 05/071032, US4,407,997; used as a source of zinc in foods as described in US 6,156,355, WO 05/058052; It is also used in the manufacture of electronic components due to its high conductivity, as described in US 6,813,137, EP 1770074, WO 06/138071. However, few documents describe their use in healing compositions.
Um desses documentos é o WO 2007/022264, que descreve umacomposição compreendendo óxidos metálicos para a cicatrização de feridas.Dentre os óxidos descritos por esse documentos estão diversos óxidos taiscomo oxido de silício, oxido de titânio e oxido de zinco. O documento deixaclaro que óxidos ácidos, como oxido de silício e oxido de titânio possuemcaracterísticas pró-trombóticas, diminuindo o tempo de coagulação, enquantoóxidos básicos, como óxidos de zinco e oxido de alumínio possuemcaracterísticas antitrombóticas, aumentando assim o tempo de coagulação.One such document is WO 2007/022264, which describes a composition comprising metal oxides for wound healing. Among the oxides described therein are various oxides such as silicon oxide, titanium oxide and zinc oxide. The document makes it clear that acid oxides such as silicon oxide and titanium oxide have prothrombotic characteristics, reducing clotting time, while basic oxides such as zinc oxides and aluminum oxide have antithrombotic characteristics, thereby increasing clotting time.
A presente invenção difere deste documento pelo fato de utilizar umextrato vegetal em combinação com outros elementos, dentre eles óxidosmetálicos, especialmente o oxido de zinco, que apresentou um comportamentodiferente do descrito no estado da técnica, promovendo assim a cicatrização.The present invention differs from this document in that it uses a plant extract in combination with other elements, among them metal oxides, especially zinc oxide, which exhibited a behavior different from that described in the prior art, thus promoting healing.
Portanto, pode-se ver que a associação de extratos de Calêndula comagentes hemostáticos e com ingredientes opcionais não havia nunca antes sidodescrita, sendo portanto a presente invenção nova e sua combinaçãotampouco sugerida, sendo a presente invenção inventiva.Therefore, it can be seen that the combination of hemostatic commingling marigold extracts and optional ingredients has never been described before, so that the present invention is novel and its combination has not been suggested either, the present invention being inventive.
Sumário da InvençãoSummary of the Invention
É um objeto da presente invenção proporcionar uma composiçãofarmacêutica compreendendo:It is an object of the present invention to provide a pharmaceutical composition comprising:
a) pelo menos um extrato vegetal de uma planta selecionada dogênero Calêndula; e(a) at least one plant extract of a selected plant of calendula; and
b) pelo menos um agente hemostático; eb) at least one hemostatic agent; and
c) pelo menos um ingrediente opcionalc) at least one optional ingredient
d) um veículo farmaceuticamente aceitável.d) a pharmaceutically acceptable carrier.
A composição farmacêutica da presente invenção apresenta açãocicatrizante, anti-séptica e hemostática.The pharmaceutical composition of the present invention has healing, antiseptic and hemostatic action.
Numa concretização opcional da presente invenção à composiçãofarmacêutica da presente invenção podem ser incorporados veículos aceitáveispara a apresentação na forma de pomadas, cremes, loções, dentre outros.In an optional embodiment of the present invention to the pharmaceutical composition of the present invention acceptable carriers may be incorporated for presentation in the form of ointments, creams, lotions, among others.
É também um outro objeto da presente invenção proporcionar umprocesso de preparação da composição farmacêutica, compreendendo asetapas de:a) misturar um extrato vegetal de uma planta selecionada dogênero Calêndula com um agente hemostático e o ingredienteopcional; eIt is also another object of the present invention to provide a process for preparing the pharmaceutical composition, comprising the steps of: a) mixing a plant extract of a selected calendula plant with a hemostatic agent and the optional ingredient; and
b) incorporar a mistura do item a) a um veículo farmaceuticamenteaceitável.b) incorporating the mixture of item a) into a pharmaceutically acceptable carrier.
É ainda outro objeto da presente invenção o uso da composiçãofarmacêutica em processos dérmicos cicatrizantes em humanos e animais.It is still another object of the present invention to use the pharmaceutical composition in dermal healing processes in humans and animals.
Esses e outros objetos da invenção serão valorizados e melhorcompreendidos pelos versados na arte a partir da descrição detalhada a seguir.These and other objects of the invention will be appreciated and better understood by those skilled in the art from the following detailed description.
Descrição Detalhada da InvençãoDetailed Description of the Invention
Os exemplos a seguir não têm a intenção de limitar a invenção, massomente de exemplificar uma das inúmeras maneiras de concretizá-la.Diversas variantes da composição/formulação farmacêutica podem serpreparadas a partir dos ensinamentos da presente invenção.The following examples are not intended to limit the invention, but to exemplify one of a number of ways of carrying it out. Several variants of the pharmaceutical composition / formulation may be prepared from the teachings of the present invention.
A composição farmacêutica descrita na presente invenção utiliza pelomenos um componente das classes de compostos relacionados abaixo:The pharmaceutical composition described in the present invention utilizes at least one component of the classes of compounds listed below:
Extrato vegetal de plantas do gênero CalêndulaPlant extract of plants of the genus Calendula
O extrato vegetal utilizado na presente invenção é obtido a partir demétodos de extração comumente conhecidos que utilizam qualquer parte dasplantas pertencentes ao gênero Calêndula. Especificamente, na presenteinvenção, são utilizadas partes de plantas da espécie Calêndula officinalis.The plant extract used in the present invention is obtained from commonly known extraction methods that utilize any part of the plants belonging to the genus Calendula. Specifically, in the present invention, parts of plants of the species Calendula officinalis are used.
O extrato vegetal da presente invenção pode ser utilizado emproporções que variam de 5 a 30%. Um uma realização preferencial, apresente invenção utiliza extrato de Calêndula officinalis em uma concentraçãode 14,46 % v/p.The plant extract of the present invention may be used in portions ranging from 5 to 30%. As a preferred embodiment, the present invention utilizes Calendula officinalis extract at a concentration of 14.46% v / w.
Agente hemostáticoHemostatic agent
O agente hemostático da presente invenção é escolhido em forma desulfato e está presente em concentrações que variam de 0,01 a 3% p/p.Preferencialmente, a composição da presente invenção compreende comoagente hemostático o sulfato de alumínio e potássio (Alúmen), em umaconcentração de 0,5% p/p.The hemostatic agent of the present invention is chosen in desulfate form and is present in concentrations ranging from 0.01 to 3% w / w. Preferably, the composition of the present invention comprises potassium aluminum sulfate (Alum) as hemostatic agent. a concentration of 0.5% w / w.
Ingredientes opcionaisOptional Ingredients
Ingredientes opcionais úteis na presente invenção incluem mas não selimitam a agentes espessantes, conservantes, agentes tixotrópicos, corantes,óxidos metálicos, como por exemplo oxido de zinco, flavorizantes, dentreoutros possíveis bem como a mistura dos mesmos. Especificamente, osingredientes opcionais são utilizados em concentrações que variam de 0,5 a 25% p/p.Optional ingredients useful in the present invention include, but are not limited to thickening agents, preservatives, thixotropic agents, colorants, metal oxides, such as zinc oxide, flavorants, among others, as well as a mixture thereof. Specifically, optional ingredients are used at concentrations ranging from 0.5 to 25% w / w.
Especificamente, a presente invenção utiliza oxido de zinco em umaconcentração de 13% p/p.Specifically, the present invention utilizes zinc oxide at a concentration of 13% w / w.
Veículo farmaceuticamente aceitávelPharmaceutically acceptable vehicle
O termo "farmaceuticamente" aceitável" é empregado aqui para aquelescompostos, materiais e composições e/ou formas de dosagem consideradosaptos para serem administrados ao paciente sem que haja o desencadeamentode efeitos adversos indesejáveis como toxicidade, irritação, resposta alérgicaou outro problema ou complicação com um risco razoável de ocorrência.Incluem-se nesta definição os veículos farmacêuticos e os veículos cosméticos.The term "pharmaceutically acceptable" is used herein for those compounds, materials and compositions and / or dosage forms considered suitable for administration to the patient without triggering of undesirable adverse effects such as toxicity, irritation, allergic response or other hazardous complication or risk. reasonable occurrence.This definition includes pharmaceutical vehicles and cosmetic vehicles.
O veículo farmaceuticamente aceitável que pode ser utilizado napresente invenção pode se apresentar em diversas formas farmacêuticas oucosméticas para uso tópico como, por exemplo, pomadas, sprays, cremes,dentre outros possíveis.The pharmaceutically acceptable carrier that may be used in the present invention may be in various pharmaceutical or cosmetic dosage forms for topical use, such as ointments, sprays, creams, among others.
A quantidade de veículo usada é suficiente para fornecer as quantidadesdesejadas dos componentes essências da presente invenção.The amount of vehicle used is sufficient to provide the desired amounts of the essential components of the present invention.
Em uma concretização preferencial, a composição da presente invençãoé uma pomada com ação cicatrizante, antisséptica e hemostática, indicada aotratamento de lesões superficiais como feridas e ulcerações dérmicas decaninos, felinos, bovinos e/ou eqüinos7 bem como de humanos que apresentemsangramento pós-cirúrgico de hematoma aural (otohematoma), orquiectomiaescrotal, neoplasias e tumores bem extensos, diminuindo e evitando osangramento.In a preferred embodiment, the composition of the present invention is a healing, antiseptic and hemostatic ointment, indicated for the treatment of superficial lesions such as decanine, feline, bovine and / or equine dermal ulcers7 as well as humans presenting with post-surgical hematoma bleeding. (otohematoma), scrotal orchiectomy, large tumors and tumors, reducing and preventing bleeding.
Exemplo 1. Pomada para uso veterinárioExample 1. Veterinary Ointment
Nesta concretização preferencial, cada 100g da pomada contém:In this preferred embodiment, each 100g of ointment contains:
Tintura de Calêndula, Calendula officinalis L....................................... 14,46 ml_Marigold Tincture, Calendula officinalis L ................................... 14.46 ml_
Oxido de zinco ..................................................................................... 13,30 gZinc oxide ............................................... ...................................... 13.30 g
Alúmen................................................................................................. 0,50 gAlum................................................. ................................................ 0, 50g
Excipientes q.s.p................................................................................... 100,00 g(monoestearato de glicerina, álcool cetoestearílico, álcool cetoestearílicoetoxilado, óleo mineral, vaselina branca, metilparabeno, propilparabeno, álcooletílico, essência de Melissinha, água purificada).Excipients qsp ................................................ .................................. 100.00 g (glycerine monostearate, cetostearyl alcohol, cetostearyl alcohol ethoxylate, oil mineral, white petroleum jelly, methylparaben, propylparaben, ethyl alcohol, Melissinha essence, purified water).
Os versados na arte valorizarão imediatamente os importantesbenefícios decorrentes do uso da presente invenção. Pequenas variações naforma de concretizá-la devem ser compreendidas como dentro do espírito dainvenção e das reivindicações anexas.Those skilled in the art will immediately appreciate the important benefits arising from the use of the present invention. Minor variations in the embodiment thereof should be understood to be within the spirit of the invention and the appended claims.
Claims (25)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BRPI0804102-4A BRPI0804102A2 (en) | 2008-09-01 | 2008-09-01 | pharmaceutical composition comprising plant extract and hemostatic agent and process for the preparation thereof |
| PCT/BR2009/000227 WO2010022485A1 (en) | 2008-09-01 | 2009-07-31 | Pharmaceutical composition comprising an extract of calendula subspecies |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BRPI0804102-4A BRPI0804102A2 (en) | 2008-09-01 | 2008-09-01 | pharmaceutical composition comprising plant extract and hemostatic agent and process for the preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0804102A2 true BRPI0804102A2 (en) | 2010-07-06 |
Family
ID=41720731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0804102-4A BRPI0804102A2 (en) | 2008-09-01 | 2008-09-01 | pharmaceutical composition comprising plant extract and hemostatic agent and process for the preparation thereof |
Country Status (2)
| Country | Link |
|---|---|
| BR (1) | BRPI0804102A2 (en) |
| WO (1) | WO2010022485A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104815182B (en) * | 2015-05-26 | 2018-06-12 | 李艳 | It is a kind of to be used for external application Chinese medicine of massive haemorrhage and preparation method thereof in performing the operation |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RO96600A2 (en) * | 1986-12-27 | 1989-03-30 | Oficiul Farmaceutic,Ro | COMPOSED TAMPONATED MEDICAMENT FOR CALCIUM TREATMENT |
| JP3893292B2 (en) * | 2002-01-17 | 2007-03-14 | ホーユー株式会社 | Hair cosmetic composition |
| JP4152324B2 (en) * | 2004-01-15 | 2008-09-17 | ロート製薬株式会社 | Composition for external use |
| JP2006117613A (en) * | 2004-10-25 | 2006-05-11 | Ichimaru Pharcos Co Ltd | Melanin production inhibitor |
-
2008
- 2008-09-01 BR BRPI0804102-4A patent/BRPI0804102A2/en not_active IP Right Cessation
-
2009
- 2009-07-31 WO PCT/BR2009/000227 patent/WO2010022485A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010022485A1 (en) | 2010-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6027716A (en) | Synergistic herbal extracts | |
| JP5551848B2 (en) | Itching prevention topical skin preparation | |
| US12514895B2 (en) | Topical herbal healing formulation | |
| US8668943B2 (en) | Hair care compositions for promoting hair growth and preventing hair loss | |
| FI126882B (en) | Microbicide oil in water dispersion | |
| Belkhodja et al. | In vitro and in vivo anti-inflammatory potential of Eucalyptus globulus essential oil | |
| JP2001122773A (en) | Therapeutically effective combinations | |
| CN106963691A (en) | Baby itching relieving spray | |
| US3809749A (en) | Topical pharmaceutical composition and method employing sap from the tree croton lechleri | |
| RU2163486C1 (en) | Agent for treatment of patients with psoriasis, vitiligo and alopecia | |
| DE68906205T2 (en) | COSMETIC AND PARAMEDICAL PREPARATIONS. | |
| RS49778B (en) | PHARMACEUTICAL DISINFECTION PREPARATION ON THE BASIS OF NA-LINES AND MEDICINAL HERBS | |
| US20040146587A1 (en) | Topical composition for relief of pain and minor skin irritations | |
| SK602020U1 (en) | Balm and its use | |
| RU2139078C1 (en) | Composition for treatment of patients with dermal sicknesses | |
| RO126996B1 (en) | Cream for the treatment of anal fissures and process for preparing the same | |
| WO2010022485A1 (en) | Pharmaceutical composition comprising an extract of calendula subspecies | |
| Yaşar et al. | Effect of My Guard® Food Supplement on Acute and Subacute Toxicity on Rats | |
| RU2287995C1 (en) | Wound-healing preparation (variants) | |
| Nadzri et al. | Preparation and evaluation of hydrogels containing methanolic extract of brassica oleracea ver. italic. | |
| RU2380108C1 (en) | Method of prevention and treatment of inflammatory processes in organism | |
| RU2373946C1 (en) | Method for prevention and treatment of inflammatory processes in organism | |
| WO2001058464A1 (en) | Water dispersed ivermectin dosage form used for curing ecto- and endoparasitic diseases | |
| Rahim et al. | Formulation and Evaluation of herbal Face Wash | |
| Mali et al. | Formulation & Evaluation of Herbal Antiseptic Cream from Giloy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B03A | Publication of an application: publication of a patent application or of a certificate of addition of invention | ||
| B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE A 3A ANUIDADE. |
|
| B08G | Application fees: restoration | ||
| B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES. |
|
| B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: REFERENTE AO DESPACHO 8.6 NA RPI 2343 DE 01/12/2015 |